| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1053263715 |
| P356 | DOI | 10.1186/S12885-015-1759-Y |
| P932 | PMC publication ID | 4617450 |
| P698 | PubMed publication ID | 26486455 |
| P5875 | ResearchGate publication ID | 283517697 |
| P2093 | author name string | Ho Yeong Lim | |
| Se Hoon Park | |||
| Jeeyun Lee | |||
| Joon Oh Park | |||
| Seung Tae Kim | |||
| Su Jin Lee | |||
| Won Ki Kang | |||
| Young Suk Park | |||
| Eunjin Lee | |||
| In-Gu Do | |||
| Hee Cheol Kim | |||
| Tae Jin Ahn | |||
| Suk Hyeong Kim | |||
| P2860 | cites work | Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. | Q38934630 |
| Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab | Q43628312 | ||
| Tousled-like kinase in a microbial eukaryote regulates spindle assembly and S-phase progression by interacting with Aurora kinase and chromatin assembly factors | Q46064321 | ||
| Approaches to complex pathways in molecular epidemiology: summary of a special conference of the American Association for Cancer Research | Q46093678 | ||
| EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer | Q46662707 | ||
| KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab | Q46903224 | ||
| Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. | Q55043614 | ||
| The NanoString-based multigene assay as a novel platform to screen EGFR, HER2, and MET in patients with advanced gastric cancer. | Q55069791 | ||
| RAF/RAS oncogenes and mismatch-repair status | Q57281056 | ||
| K-ras mutations and cetuximab in colorectal cancer | Q94852396 | ||
| Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer | Q21142734 | ||
| The protein kinase complement of the human genome | Q24324497 | ||
| PSKH1, a novel splice factor compartment-associated serine kinase | Q24540428 | ||
| Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer | Q27851456 | ||
| PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies | Q27851465 | ||
| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis | Q27851573 | ||
| KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. | Q27851616 | ||
| Global cancer statistics, 2002 | Q27860562 | ||
| Oncogenic kinase signalling | Q28189493 | ||
| Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer | Q28240089 | ||
| Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer | Q28271324 | ||
| Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer | Q28305293 | ||
| Direct multiplexed measurement of gene expression with color-coded probe pairs | Q29614417 | ||
| Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status | Q29619648 | ||
| Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study | Q29619653 | ||
| Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials | Q31014850 | ||
| Making sense of cancer genomic data | Q33846850 | ||
| Characterization of PSKH1, a novel human protein serine kinase with centrosomal, golgi, and nuclear localization | Q33925946 | ||
| Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer | Q34094717 | ||
| Mutants of the protein serine kinase PSKH1 disassemble the Golgi apparatus | Q34279657 | ||
| A module map showing conditional activity of expression modules in cancer | Q34353143 | ||
| Molecular classification of prostate cancer using curated expression signatures | Q35641563 | ||
| Forensic genetics and ethical, legal and social implications beyond the clinic | Q36503211 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colorectal cancer | Q188874 |
| cetuximab | Q420296 | ||
| biomarker | Q864574 | ||
| metastatic colon cancer | Q108566365 | ||
| P304 | page(s) | 747 | |
| P577 | publication date | 2015-10-20 | |
| P1433 | published in | BMC Cancer | Q326300 |
| P1476 | title | Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan | |
| P478 | volume | 15 |
| Q38966146 | HIVE-heptagon: A sensible variant-calling algorithm with post-alignment quality controls |
| Q92187262 | MiR-566 mediates cell migration and invasion in colon cancer cells by direct targeting of PSKH1 |
| Q41721762 | The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer |
| Q92566236 | miRDRN-miRNA disease regulatory network: a tool for exploring disease and tissue-specific microRNA regulatory networks |
Search more.